SLC5A2 and deep vein thrombosis: Liao et al.32included nine RCTs3, 7, 8, 113, 115, 117, 118, 119(note that trials NCT01032629 and NCT01989754 are in one publication113) in their meta-analysis, reporting no association (vs. placebo) between SGLT2 inhibitors and DVT risk (61/33,124 vs. 48/26,568; RR 1.03, 95% CI 0.69–1.53).